- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02362971
External Validity of a Randomized Trial in Patients With a Femoral Neck Fracture (EXVAL)
External Validity of a Randomized Controlled Trial in Patients With a Femoral Neck Fracture
The aim of this study is to evaluate the external validity of a randomized controlled trial comparing choice of hip arthroplasty for elderly patients (>80 years) with a displaced femoral neck fracture.
The hypotheses are that patient reported hip function, quality of life are better and healthier in those included in the randomized controlled trial than those excluded. The external validity of the randomized controlled trial is acceptable.
A prospective randomized controlled trial is planned and patients with a displaced femoral neck fracture will be included and randomized between either a hemiarthroplasty or total hip arthroplasty. All patients screened will be included in a prospective cohort study for evaluation of the external validity of the randomized controlled trial. The prospective cohort study will consist of 3 different groups.
Patients included in the randomized controlled trial will form group 1. Patients eligible for the randomized controlled trial but did not give their informed consent and therefore excluded, form group 2.
Patients with a femoral neck fracture which by any reason were excluded form group 3.
Primary endpoint is patient-reported hip function (Harris hip score) and pain on the operated extremity evaluated with VAS (Visual Analogue Scale) and patient reported quality of life evaluated with EuroQol (EQ-5D). Secondary outcome measurement are the frequency of the complications, periprosthetic fracture, dislocation, revision surgery due to wound infection (deep and superficial) and loosening of the components. Baseline data, age, sex, comorbidity, cognitive status, weight, height, motor function, complications and reoperations. Follow up is performed 1-2 years after surgery.
Group 1 is followed up in the ongoing randomized controlled trial by visits to the orthopedic department at Danderyd Hospital. Group 2 and 3 are followed up by telephone interview 1-2 year after surgery.
Study Overview
Status
Conditions
Detailed Description
The aim of this study is to evaluate the external validity of a randomized controlled trial comparing choice of hip arthroplasty for elderly patients (>80 years) with a displaced femoral neck fracture.
The hypotheses are:
- The patient reported hip function and quality of life are better in those included in the randomized controlled trial than those excluded.
- Patients included in the study are healthier than those excluded.
- The external validity of the randomized controlled trial is acceptable, defined as the difference between patients that provide and do not provide their informed consent do not reach clinical significance (a mean difference in Harris hip score of 10 points).
All patients above 80 years old with an acute displaced femoral neck fracture at Danderyds hospital AB during 2009-2016 will be screened and asked for participation in a randomized controlled trial. Those who fulfill the criteria for inclusion and give their informed consent are enrolled in the randomized controlled trial. Patients that will not give their informed consent and those which do not fulfill the inclusion criteria are enrolled in a prospective cohort study for evaluation of the external validity.
The prospective cohort study will consist of 3 different groups. Patients included in the randomized controlled trial study will form group 1. Patients eligible for the randomized controlled trial but did not give their informed consent and therefore excluded, form group 2.
Patients with a femoral neck fracture which by any reason were excluded form group 3.
Follow-up is performed 1-2 years after surgery. Inclusion criteria in the randomized controlled trial.
1. Age above 80 years 2. Acute (<36h) displaced femoral neck fracture. 3. Independent walker 4. Abscence of cognitive impairment (Pfeiffer test >7) 5. Did not fulfill any exclusion criteria Exclusion criteria in the randomized controlled trial
- Patient with osteoarthritis or rheumatoid arthritis in the fractured hip
- Pathological fracture
- Non walker
- Cognitive impairment (Short Portable Mental Questionnaire <7)
- Contraindication to total hip replacement due to wound, patients with comorbidities, deemed not suitable for a total hip replacement by the anesthesiologist, severe coagulation disorder, and severe drug abuse.
Deemed unsuitable for inclusion by other reason.
- Primary endpoint is patient-reported hip function (Harris hip score) and pain on the operated extremity evaluated with VAS (Visual Analogue Scale)
- Patient reported quality of life evaluated with EQ-5D.
Secondary outcome:
- Secondary outcome measurement are the frequency of the complications, periprosthetic fracture, dislocation, revision surgery due to wound infection (deep and superficial) and loosening of the components.
- Baseline data, age, sex, comorbidity, cognitive status, weight, height, motor function and complications and reoperations.
Secondary outcome measurements are obtained in the medical records.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 18288
- Orthopaedic department, Danderyd Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria randomized controlled trials:
- Age above 80 years
- Acute (<36h) displaced femoral neck fracture.
- Independent walker
- Abscence of cognitive impairment (Short Portable Mental Questionnaire >7points)
- Did not fulfill any exclusion criteria
Exclusion Criteria randomized controlled trial:
- Patient with osteoarthritis or rheumatoid arthritis in the fractured hip
- Pathological fracture
- Non walker
- Cognitive impairment (Short Portable Mental Questionnaire <7points)
- Contraindication to total hip replacement due to wound, patients with comorbidities, deemed not suitable for a total hip replacement by the anesthesiologist, severe coagulation disorder, and severe drug abuse.
- Deemed unsuitable for inclusion by other reason.
Inclusion into prospective cohort study
- Included into the randomized controlled trial.
- Did not give their informed consent for participation in the randomized controlled trial.
- Patients above 80 years of age excluded from participation in the randomized controlled trial due to fulfillment of exclusion criteria or did not fulfill inclusion criteria.
Exclusion into prospective cohort study
- Age below 80 years of age.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Included
Patients included into the randomized controlled trial
|
|
Non-consenters
Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
|
|
Excluded
Patients, by different reasons excluded from participation in the randomized controlled trial.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Harris hip score
Time Frame: Up to 2 years
|
Hip function as a patient reported outcome measurement
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Baseline data (Preoperative baseline data obtained at admission to the hospital)
Time Frame: 1 day
|
Age, sex, date of surgery, type of surgical treatment, surgical approach, time, level of competence of the treating surgeon, American Society of Anesthesiologists grade determined by treating anesthesiologist, surgical time, patients weight and length
|
1 day
|
|
Mortality
Time Frame: up to 2 years
|
up to 2 years
|
|
|
Complications (Any reason to reoperation)
Time Frame: up to 4 years years
|
Any reason to reoperation most commonly prosthetic dislocation, deep infection, periprosthetic dislocation
|
up to 4 years years
|
|
EQ-5D
Time Frame: up to 2 years
|
Health related quality of life, patient reported outcome
|
up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Olof G Skoldenberg, MD, PhD, Department of clinical sciences at Danderyds hospital, Karolinska Institutet
Publications and helpful links
General Publications
- Evidence-based health care: a new approach to teaching the practice of health care. Evidence-Based Medicine Working Group. J Dent Educ. 1994 Aug;58(8):648-53. No abstract available.
- Petersen MK, Andersen KV, Andersen NT, Soballe K. "To whom do the results of this trial apply?" External validity of a randomized controlled trial involving 130 patients scheduled for primary total hip replacement. Acta Orthop. 2007 Feb;78(1):12-8. doi: 10.1080/17453670610013367.
- Pibouleau L, Boutron I, Reeves BC, Nizard R, Ravaud P. Applicability and generalisability of published results of randomised controlled trials and non-randomised studies evaluating four orthopaedic procedures: methodological systematic review. BMJ. 2009 Nov 17;339:b4538. doi: 10.1136/bmj.b4538.
- van den Bekerom MP, Hilverdink EF, Sierevelt IN, Reuling EM, Schnater JM, Bonke H, Goslings JC, van Dijk CN, Raaymakers EL. A comparison of hemiarthroplasty with total hip replacement for displaced intracapsular fracture of the femoral neck: a randomised controlled multicentre trial in patients aged 70 years and over. J Bone Joint Surg Br. 2010 Oct;92(10):1422-8. doi: 10.1302/0301-620X.92B10.24899. Erratum In: J Bone Joint Surg Br. 2011 Jan;93(1):140.
- Gao H, Liu Z, Xing D, Gong M. Which is the best alternative for displaced femoral neck fractures in the elderly?: A meta-analysis. Clin Orthop Relat Res. 2012 Jun;470(6):1782-91. doi: 10.1007/s11999-012-2250-6. Epub 2012 Jan 26.
- Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005 Jan 1-7;365(9453):82-93. doi: 10.1016/S0140-6736(04)17670-8.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- External validity
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hip Fracture
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingHip Fractures | Pathological Fracture | Pathological Fracture of Hip | Hip Fracture PathologicUnited States
-
The University of Hong KongRecruiting
-
Istanbul Rumeli UniversityFatih Sultan Mehmet Training and Research Hospital; Istanbul University - CerrahpasaCompletedHip Fracture | Hip Fracture SurgeriesTurkey (Türkiye)
-
Mayo ClinicCompletedPertrochanteric Hip FractureUnited States
-
Eurofarma Laboratorios S.A.TerminatedHip Fracture SurgeryBrazil
-
National Institute of Arthritis and Musculoskeletal...Completed
-
AO Clinical Investigation and Publishing DocumentationCompletedHip Fractures | Closed Fracture of HipIsrael, Austria, Switzerland, Germany, Belgium, Norway
-
JointResearchActive, not recruitingHip Fracture | Hip Fracture SurgeriesNetherlands
-
Sakarya UniversityNot yet recruitingHip Fracture SurgeriesTurkey